CEO & Co-Founder
Oriana has global experience creating and leading teams and organizations resulting in successful strategic exits. She brings a wealth of knowledge and expertise from women's health startups and large life science companies, and a passion for entrepreneurship and solving problems that disproportionality affect women. Recognized for her inspirational leadership, Oriana is known for developing a highly productive culture and turning visions into reality.
Alongside her leadership qualities, Oriana has a proven technical record of creating market entry strategies and product launches in new markets alongside driving market share growth in existing diagnostic assay and instrument markets.
Oriana is responsible for building and leading the AOA team, fundraising and developing and executing long-term strategies.
Oriana holds a degree from Boston University in Economics and International Relations, and she has experience both living and working in various geographies.
COO & Co-Founder
Alex is a passionate and dedicated business leader with a track record of launching UK medical device and diagnostics sales companies. He has extensive experience priming markets, launching products and driving early product sales.
In most recent roles, Alex has been committed to commercializing and launching innovative, disruptive products through his own businesses across European healthcare markets with a primary focus on obstetrics and gynecology.
Alex works closely with Oriana, ensuring strategies relating to finance, accounting, legal and fundraising are executed in a timely manner. On a daily basis, Alex ensures AOA's operations are running smoothly and efficiently.
Alex has a degree and MSc from the University of Southampton and University College London.
CBO & Co-Founder
Anna is dynamic business leader with a passion for advancing healthcare through world-class diagnostics.
Most recently Anna led multiple business development teams for companies focused on novel diagnostic devices including maternal fetal medicine and inflammatory autoimmune diseases, encompassing product development, clinical development, economic modeling, marketing and launch.
Anna has overseen the inclusion of multiple product into national and pan-European guidelines, and she has experience with US FDA submissions for 510(k), PMA, and CLIA LTD regulatory routes.
As CBO, Anna has overall responsibility for fulfilling AOA's scientific mission, product development and building shareholder value.
Anna holds a degree in International Finance and Business Administration from Boston University Questrom School of Management.
Professor Uri Saragovi, PhD
Dr. Saragovi is a passionate and world-leading scientist in the area of Translational Medicine.
Dr. Saragovi has published over 200 publications and 21 patents, primarily focusing translational medicine. More recently Dr. Saragovi has focused on the targeting of gangliosides, which are used clinically for cancer diagnosis, prognosis, and therapy.
Dr. Saragovi based at McGill University and Lady Davis Institute at the Jewish General Hospital, Montreal.
Nancy Schoenbrunner, PhD
Diagnostic Assay Advisor
Dr. Schoenbrunner, CEO of AmplifiDx Inc. and President of NJS Consulting LLC, has a proven track record as an executive in the medical device and diagnostic field.
Nancy is adept at fundraising, planning and directing the organization’s technology commercialization and innovation strategy, R&D and IP portfolio. She is inventor on 26 issued and pending patent families.
Chief Financial Officer
Mr. Marchio brings 40+ years of experience in the biomedical and life science industries as a CFO.
Bert is an Entrepreneurial Financial Executive who has led finance functions for early stage, private equity sponsored, and international NYSE listed companies. His accomplishments include $82 million IPO and $56 million crossover financing, as well as raising over $40 million in Series A, B and C rounds of financing. Bert's experience extends to Finance Management, Investor Relations, Risk Management, Fund Raising, Tax Compliance and Mergers & Acquisitions.
Therapeutic Development Advisor
Mrs. Chapelle developed her career in sales & marketing with UCB before obtaining senior positions at Pfizer.
Sophie then proceeded to build a highly reputable clinical trials business, working with leading pharmaceutical companies.
Most recently, Sophie drove the commercial strategy and execution for Scipher Medicine's personalized medicine platform in autoimmune diseases, enabling successful series A and B investments in less than two years.